In the last trading session, 2.16 million shares of the Ginkgo Bioworks Holdings Inc (NYSE:DNA) were traded, and its beta was 1.24. Most recently the company’s share price was $8.01, and it changed around -$0.23 or -2.79% from the last close, which brings the market valuation of the company to $460.40M. DNA currently trades at a discount to its 52-week high of $64.40, offering almost -704.0% off that amount. The share price’s 52-week low was $5.26, which indicates that the current value has risen by an impressive 34.33% since then.
Ginkgo Bioworks Holdings Inc stock received a consensus recommendation rating of Underweight, based on a mean score of 4.00. If we narrow it down even further, the data shows that 1 out of 6 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended DNA as a Hold, whereas 1 deemed it a Buy, and 3 rated it as Underweight. Ginkgo Bioworks Holdings Inc is expected to report earnings per share of 0 for the current quarter.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Instantly DNA has showed a red trend with a performance of -2.79% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 10.56 on recent trading dayincreased the stock’s daily price by 24.15%. The company’s shares are currently down -18.43% year-to-date, but still down -23.42% over the last five days. On the other hand, Ginkgo Bioworks Holdings Inc (NYSE:DNA) is -42.42% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $6.5, which translates to bulls needing to decrease their stock price by -23.23% from its current value. Analyst projections state that DNA is forecast to be at a low of $4.35 and a high of $12.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
The year-over-year growth rate is expected to be -20.99%, down from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 39.34M in revenue for the current quarter. 5 analysts expect Ginkgo Bioworks Holdings Inc to make 43.62M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 37.94M and 56.21M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 3.67%. Forecasts for the next quarter put sales growth at -22.40%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -27.97%. Ginkgo Bioworks Holdings Inc earnings are expected to increase by 41.63% in 2025, but the outlook is positive 39.28% per year for the next five years.
DNA Dividends
Ginkgo Bioworks Holdings Inc’s next quarterly earnings report is expected to be released in April.
VANGUARD GROUP INC, with 6.9327% or 138.96 million shares worth $46.46 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 1.17 shares worth $9.36 million, making up 2.55% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 526.35 shares worth around $4.22 million, which represents about 1.15% of the total shares outstanding.
